GALAPAGOS NV ADS (GLPG) Covered Calls

You can sell covered calls on GALAPAGOS NV ADS to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for GLPG (prices last updated Fri 4:16 PM ET):

GALAPAGOS NV ADS (GLPG) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
101.34 -0.40 101.34 101.34 50K - 5.3B
Covered Calls For GALAPAGOS NV ADS (GLPG)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Sep 21 100 4.60 96.74 3.4% 34.5%
Oct 19 100 6.10 95.24 5.0% 28.5%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.